A detailed history of Crawford Investment Counsel Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Crawford Investment Counsel Inc holds 6,236 shares of BMY stock, worth $360,191. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,236
Previous 6,235 0.02%
Holding current value
$360,191
Previous $258,000 24.81%
% of portfolio
0.01%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $39 - $51
1 Added 0.02%
6,236 $322,000
Q2 2024

Aug 14, 2024

SELL
$40.25 - $52.99 $141,398 - $186,153
-3,513 Reduced 36.04%
6,235 $258,000
Q1 2024

May 15, 2024

BUY
$47.98 - $54.4 $20,391 - $23,120
425 Added 4.56%
9,748 $528,000
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $86,148 - $102,799
-1,777 Reduced 16.01%
9,323 $478,000
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $11,751 - $13,140
203 Added 1.86%
11,100 $644,000
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $76,006 - $84,392
-1,193 Reduced 9.87%
10,897 $696,000
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $26,678 - $30,259
-406 Reduced 3.25%
12,090 $837,000
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $37,664 - $44,599
-550 Reduced 4.22%
12,496 $898,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $8 - $5,071
66 Added 0.51%
13,046 $927,000
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $73,636 - $81,099
-1,014 Reduced 7.25%
12,980 $999,000
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $40,023 - $47,991
651 Added 4.88%
13,994 $1.02 Million
Q4 2021

Feb 07, 2022

SELL
$53.63 - $62.52 $57,169 - $66,646
-1,066 Reduced 7.4%
13,343 $832,000
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $8,461 - $9,911
143 Added 1.0%
14,409 $853,000
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $4,024 - $4,382
65 Added 0.46%
14,266 $953,000
Q1 2021

May 14, 2021

SELL
$59.34 - $66.74 $89,484 - $100,643
-1,508 Reduced 9.6%
14,201 $897,000
Q4 2020

Feb 01, 2021

BUY
$57.74 - $65.43 $17,783 - $20,152
308 Added 2.0%
15,709 $974,000
Q3 2020

Oct 29, 2020

SELL
$57.43 - $63.64 $41,177 - $45,629
-717 Reduced 4.45%
15,401 $929,000
Q2 2020

Aug 13, 2020

SELL
$54.82 - $64.09 $9,209 - $10,767
-168 Reduced 1.03%
16,118 $948,000
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $2,691 - $3,910
-58 Reduced 0.35%
16,286 $908,000
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $16,485 - $21,503
335 Added 2.09%
16,344 $1.05 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $4,277 - $5,071
100 Added 0.63%
16,009 $812,000
Q2 2019

Aug 12, 2019

BUY
$44.62 - $49.34 $52,205 - $57,727
1,170 Added 7.94%
15,909 $721,000
Q1 2019

May 09, 2019

SELL
$45.12 - $53.8 $13,536 - $16,140
-300 Reduced 1.99%
14,739 $703,000
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $21,405 - $27,757
439 Added 3.01%
15,039 $782,000
Q2 2018

Aug 14, 2018

SELL
$50.53 - $62.98 $14,805 - $18,453
-293 Reduced 1.97%
14,600 $808,000
Q1 2018

May 15, 2018

SELL
$59.92 - $68.98 $167,835 - $193,212
-2,801 Reduced 15.83%
14,893 $942,000
Q4 2017

Feb 13, 2018

SELL
$59.94 - $65.35 $137,862 - $150,305
-2,300 Reduced 11.5%
17,694 $1.08 Million
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $1.1 Million - $1.27 Million
19,994
19,994 $1.27 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Crawford Investment Counsel Inc Portfolio

Follow Crawford Investment Counsel Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crawford Investment Counsel Inc, based on Form 13F filings with the SEC.

News

Stay updated on Crawford Investment Counsel Inc with notifications on news.